HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed viral dynamics and HCV-specific immune response during retreatment for experienced patients in a phase Ib study with E1E2MF59 vaccine. Seventy-eight genotype 1a/1b patients [re...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombatto, P, Brunetto, M R, Maina, A M, Romagnoli, V, Almasio, P, Rumi, M G, Ascione, A, Pinzello, G, Mondelli, M, Muratori, L, Rappuoli, R, Rosa, D, Houghton, M, Abrignani, S, Bonino, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166695/
https://www.ncbi.nlm.nih.gov/pubmed/24750327
http://dx.doi.org/10.1111/jvh.12163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166695/
https://www.ncbi.nlm.nih.gov/pubmed/24750327
http://dx.doi.org/10.1111/jvh.12163

Ejemplares similares